The organizations challenge a presidential executive order narrowing routine childhood vaccine recommendations and urging vaccines to be given separately.
Three national medical organizations are challenging a new executive order that reshapes federal
President Donald Trump signed an executive order on August 10, 2026, establishing what the administration calls the “Gold Standard Childhood Vaccine Recommendations.” The framework divides childhood and adolescent immunizations into 3 categories: those recommended for all children, those recommended for high-risk groups or populations, and those administered through shared clinical decision-making.¹
The order maintains universal recommendations for immunization against
The order also states that the combined measles, mumps, and rubella (MMR) vaccine should be administered as 3 single-disease injections once those products are domestically available. It further recommends that, “to the maximum extent feasible,”
In statements issued after the order was signed, the American Academy of Pediatrics (AAP), American Medical Association (AMA), and National Foundation for Infectious Diseases (NFID) questioned the scientific basis for changing the existing schedule. The AMA and NFID also reaffirmed their support for the AAP childhood immunization recommendations.²⁻⁴
AAP President Andrew Racine, MD, PhD, FAAP, called the order “not only disheartening but dangerous,” citing the 35-year high in US measles cases and the approach of the next influenza and respiratory virus season.²
Racine said no new evidence justifies significant changes to childhood immunization guidance and criticized federal officials for continuing to promote the
The AAP emphasized that vaccine timing is based on the ages at which children’s immune systems are expected to respond best and the periods when children are most vulnerable to specific diseases. Depending on those considerations, children may receive a combination vaccine or multiple vaccines during the same visit.²
“Delaying or skipping shots is risky, especially as measles continues to spread and children go back to school,” Racine said.²
According to Racine, the AAP schedule is tailored to the health needs of children living in the US and is based on decades of research and systematic monitoring of real-world vaccine use. He emphasized that on-time immunization protects both children and communities and encouraged parents with questions to consult their child’s pediatrician or clinician.²
AMA President Willie Underwood III, MD, MSc, MPH, said decisions about the use and timing of childhood vaccines should be based on rigorous scientific evidence, patient safety, and independent medical and public health expertise.³
“Altering a proven vaccination schedule without credible evidence risks weakening public confidence and putting children’s health at risk,” Underwood said.³
The AMA emphasized that the AAP schedule remains based on disease risks and health care delivery within the US. Underwood also reiterated that decades of scientific research have found no association between vaccination and autism and encouraged parents with questions to consult their child’s physician.³
NFID offered similar criticism but focused more directly on the differences between the US and the peer countries the administration used to inform its revised framework.
NFID Medical Director Robert H. Hopkins Jr, MD, said evidence from other countries can provide useful insight, but population characteristics, disease patterns, health care systems, and immunization programs vary. A schedule based on another country’s circumstances will not necessarily provide the same protection in the US, according to Hopkins.⁴
NFID also argued that the number of vaccines or doses on a schedule does not determine whether the schedule is scientifically sound. Instead, each recommendation should be evaluated according to the benefits and risks of vaccination in the context of the diseases affecting US children.⁴
“Changes made without that evidence risk weakening the protections children have today,” Hopkins said.⁴
The organization cited the current resurgence of vaccine-preventable disease as a central concern. According to the NFID statement, the US is experiencing its largest
NFID further warned that changes making vaccines more difficult to obtain could decrease uptake and allow diseases previously held in check to re-emerge. The organization called for any revisions to longstanding recommendations to undergo rigorous and transparent review by independent experts and to be supported by evidence that the changes would improve protection.⁴
The executive order does not immediately remove vaccines from the market, establish a complete dosing schedule, or change state school-entry requirements. It directs federal agencies to review and advance the recommendations within their legal authority and advises states and territories to reconsider relevant vaccination requirements.¹
The HHS Task Force on Safer Childhood Vaccines must present implementation plans to the White House within 90 days, or by November 8, 2026. The plans must address single-antigen vaccine options beginning with MMR, the timing and sequencing of childhood vaccines, alternatives to aluminum-containing adjuvants, continuous benefit-risk evaluation, and vaccine safety monitoring and research.¹
The order guarantees the continued availability of combination vaccines and vaccines recommended through shared clinical decision-making, but it does not establish future insurance coverage or cost-sharing requirements. It also leaves unanswered how separate vaccination visits would be implemented in clinical practice.
